Utilizing aptamers in targeted protein degradation strategies for disease therapy
The Journal of Pathology · 2025
DOI: 10.1002/path.6422 ↗At a glance
Übersichtsarbeit in The Journal of Pathology, 2025. Written by Lin Li and 3 co-authors. Institution: Center for Cell Structure and Function, Shandong Provincial Key Laboratory of Animal Resistance Biology, College of Life Sciences, Shandong Normal Un…. Major MEDLINE topics: Aptamers, Nucleotide, Proteolysis, Neoplasms. Cited 13 times so far (Crossref); 71 references. Funded by: National Natural Science Foundation of China.
Abstract (original language)
Targeted protein degradation (TPD) has emerged as a promising therapeutic strategy, offering the potential to reduce disease‐causing proteins that have traditionally been challenging to target using conventional small molecules. Despite significant advances made with TPD technologies, challenges such as high molecular weight, difficulties in identifying suitable ligands, suboptimal absorption, and metabolic instability remain unresolved. Recently, aptamers – single‐stranded DNA or RNA oligonucleotides known for their high specificity and affinity for protein targets – have introduced novel opportunities to expand the scope of TPD, a strategy now referred to as aptamer‐based TPD. This approach has demonstrated considerable promise in treating various diseases, such as cancer and ocular disorders. For example, an aptamer‐proteolysis‐targeting chimera (PROTAC) conjugate (APC) improved tumor targeting and reduced toxicity in a breast cancer model, and a vascular endothelial growth factor‐degrading (VED)‐lysosome‐targeting chimera (LYTAC) molecule effectively inhibited abnormal vascular growth in vascular retinal diseases. These examples highlight the practical relevance and potential in advancing drug discovery efforts. In this review we provide a comprehensive overview of the latest advances in aptamer‐based TPD strategies, including proteolysis‐targeting and lysosome‐targeting chimeras, emphasizing their applications, potential therapeutic benefits, as well as the challenges that must be overcome to fully harness their clinical potential. © 2025 The Pathological Society of Great Britain and Ireland.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Center for Cell Structure and Function, Shandong Provincial Key Laboratory of Animal Resistance Biology, College of Life Sciences, Shandong Normal University, Jinan, PR China.
- Department of Genetics and Cell Biology, College of Life Sciences, State Key Laboratory of Medicinal Chemical Biology, Haihe Laboratory of Cell Ecosystem, Nankai University, Tianjin, PR China.
ORCID profiles: Jie Ran
Funding
- National Natural Science Foundation of China
Cite
APA
Li, L., Xie, S., Zhou, J., & Ran, J. (2025). Utilizing aptamers in targeted protein degradation strategies for disease therapy. The Journal of Pathology. https://doi.org/10.1002/path.6422
Vancouver
Li L, Xie S, Zhou J, Ran J. Utilizing aptamers in targeted protein degradation strategies for disease therapy. The Journal of Pathology. 2025. doi:10.1002/path.6422
BibTeX
@article{Li2025,
author = {Li, Lin and Xie, Songbo and Zhou, Jun and Ran, Jie},
title = {Utilizing aptamers in targeted protein degradation strategies for disease therapy},
journal = {The Journal of Pathology},
year = {2025},
doi = {10.1002/path.6422}
}
EUVIMED